Literature DB >> 3502450

Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats.

N R Worrell1, A J Cumber, G D Parnell, A Mirza, J A Forrester, W C Ross.   

Abstract

We have investigated the pharmacokinetics of three ricin A chain-antibody conjugates having different bridging structures. Conjugate 1 has a disulphide linkage and was prepared with the N-succinimidyl-3-(2-pyridyldithio)propionate cross-linking reagent. Conjugate 2 has a protected disulphide linkage with a methyl group substituted on the carbon atom of the bridging structure adjacent to the disulphide linkage. Its preparation necessitated the synthesis of a new cross-linking reagent N-succinimidyl 3-(2-pyridyldithio)-butyrate. Conjugate 3 has a sulphide linkage and was prepared with the cross-linking reagent N-succinimidyl 4-(iodoacetylamino)benzoate which was synthesized by a novel route. Conjugate 1 is reducible, conjugate 2 less easily reducible and conjugate 3 nonreducible. On administration to animals all three conjugates displayed biphasic kinetics. The reducibility of the bond had no significant effect on the early disappearance of the conjugate from the circulation. However, at the later time points ease of reduction of the bond was associated with a more rapid disappearance of conjugate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3502450

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  8 in total

Review 1.  Immunotoxins: new therapeutic reagents for autoimmunity, cancer, and AIDS.

Authors:  E S Vitetta
Journal:  J Clin Immunol       Date:  1990-11       Impact factor: 8.317

2.  Intracellular Cleavable CpG Oligodeoxynucleotide-Antigen Conjugate Enhances Anti-tumor Immunity.

Authors:  Katrin Kramer; Nicholas J Shields; Viola Poppe; Sarah L Young; Greg F Walker
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454

3.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

4.  Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.

Authors:  P Brusa; F Dosio; F Pietribiasi; L Delprino; P Feraiorni; M Mariani; G Bussolati; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Iterative Reducible Ligation to form Homogeneous Penicillamine Cross-linked Polypeptides.

Authors:  Mark D Ericson; Kevin G Rice
Journal:  Tetrahedron Lett       Date:  2013-06-26       Impact factor: 2.415

6.  Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.

Authors:  K Mujoo; L Cheung; J L Murray; M G Rosenblum
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

7.  Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.

Authors:  J A Calvete; D R Newell; C J Charlton; A F Wright
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

Authors:  E J Wawrzynczak; U Zangemeister-Wittke; R Waibel; R V Henry; G D Parnell; A J Cumber; M Jones; R A Stahel
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.